Melanoma Serum
Melanoma Serum is collected from clinically confirmed melanoma donors and frozen within 24 hours. Suited to tumour-immunology serology: LDH and S100B prognostic work, soluble PD-L1 and checkpoint quantification, tumour-associated cytokine profiling, and anti-tumour antibody detection. Stratification by stage, BRAF/NRAS status, subtype and treatment, with matched healthy controls available.
Human Melanoma Serum for Tumour Immunology Research
Our Melanoma Serum is sourced from IRB-consented donors clinically diagnosed with melanoma. Each sample is processed and frozen within 24 hours of collection to preserve labile analytes and to keep lot-to-lot handling consistent, making it suitable for studies of the systemic and immunological consequences of melanoma. Serum is acellular, so it is supplied for soluble-analyte work: immunoassays, serology, proteomics and metabolomics.
Why Melanoma Serum for Tumour Immunology Research
Melanoma develops when melanocytes undergo malignant transformation, typically against a background of high ultraviolet-associated mutational burden and frequent MAPK-pathway driver mutations. The resulting tumour is strongly immunologically engaged, and much of that host-tumour dialogue is measurable as secreted protein in serum.
- Established prognostic markers — lactate dehydrogenase is a well-recognised prognostic indicator in advanced melanoma, and S100B is widely studied as a melanoma-associated serum marker.
- Soluble immune-checkpoint molecules — soluble PD-L1, PD-1 and CTLA-4 ectodomains circulate and are directly relevant to checkpoint-inhibitor pharmacodynamics.
- Tumour-associated cytokines and chemokines — IL-6, IL-8, IL-10, TNF-α, VEGF and interferon-inducible chemokines report on tumour-driven inflammation and immune evasion, not on autoimmunity.
- Anti-tumour humoral responses — antibodies against melanoma-associated antigens are detectable in serum and support antigen-discovery and serology workflows.
- Angiogenic and stromal mediators — VEGF and matrix-remodelling proteases reflect the invasive and metastatic phenotype that distinguishes melanoma from benign melanocytic lesions.
- Serum-specific advantages — because clotting is allowed to complete, serum is the conventional matrix for many established clinical chemistry and serology platforms, easing bridging to legacy datasets.
Donor Stratification Available
- Stage at collection — localised, regional nodal, and metastatic disease
- Driver mutation status — BRAF-mutant, NRAS-mutant, and wild-type donors where genotyping is documented
- Histological subtype — cutaneous melanoma, plus acral, mucosal and uveal melanoma donors subject to availability
- Treatment status — treatment-naive, on immune-checkpoint inhibitor therapy, on targeted BRAF/MEK inhibitor therapy, or post-treatment
- Disease trajectory — responding, progressing, and post-resection disease-free donors; serial draws from the same donor where collected
- Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity
Product Features
- Collected from clinically confirmed melanoma donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes; volumes reported per lot
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Stage, subtype and treatment context reported per lot where captured
- Additional melanoma-specific clinical fields available on request
Applications
- Prognostic biomarker qualification including LDH and S100B workflows
- Soluble immune-checkpoint quantification for immuno-oncology programmes
- Serum cytokine, chemokine and angiogenic-factor profiling
- Anti-tumour antibody detection and melanoma antigen discovery
- Serum proteomic and metabolomic discovery across melanoma stages
- Therapeutic candidate screening and pharmacodynamic readout development
- Immunoassay and ELISA development with disease-state matrix
- Diagnostic reference, calibrator and control material sourcing
Other Melanoma Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Melanoma serum is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.